Brean Capital assumed coverage on shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) in a research report released on Monday morning. The firm issued a buy rating and a $8.00 target price on the stock.
IPCI has been the subject of a number of other research reports. Zacks Investment Research cut Intellipharmaceutics International from a buy rating to a hold rating in a research report on Wednesday, September 14th. Maxim Group reiterated a buy rating on shares of Intellipharmaceutics International in a research report on Friday, July 22nd.
Shares of Intellipharmaceutics International (NASDAQ:IPCI) traded up 2.400% during mid-day trading on Monday, reaching $2.304. The company’s stock had a trading volume of 142,168 shares. The company’s market cap is $66.23 million. Intellipharmaceutics International has a 52-week low of $1.41 and a 52-week high of $3.19. The company has a 50-day moving average price of $1.90 and a 200 day moving average price of $1.83.
Intellipharmaceutics International (NASDAQ:IPCI) last issued its quarterly earnings results on Wednesday, July 13th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 325.20%. Equities analysts expect that Intellipharmaceutics International will post ($0.28) earnings per share for the current year.
A hedge fund recently bought a new stake in Intellipharmaceutics International stock. Atria Investments LLC purchased a new stake in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned about 0.27% of Intellipharmaceutics International as of its most recent filing with the SEC. Institutional investors own 1.30% of the company’s stock.
About Intellipharmaceutics International
Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.